Various embodiments relate to a compound (represented by Formula I) or a pharmaceutically acceptable salt or tautomer thereof. The compound may selectively inhibit a Forkhead Box O1 (FOXO1) transcription factor. Various embodiments relate to methods comprising administering to a mammal having a disease or disorder associated with impaired pancreatic endocrine function, a therapeutically effective amount of the compound or a pharmaceutically acceptable salt or tautomer thereof. Various embodiments relate to methods for producing enteroendocrine cells that make and secrete insulin in a mammal, comprising administering to the mammal an effective amount of the compound or a pharmaceutically acceptable salt or tautomer thereof.
各种实施方式涉及一种化合物(由式I表示)或其药用可接受的盐或互变异构体。该化合物可能选择性地抑制Forkhead Box O1(FOXO1)转录因子。各种实施方式涉及方法,包括向患有与胰腺内分泌功能受损相关的疾病或疾病的哺乳动物施用该化合物或其药用可接受的盐或互变异构体的治疗有效量。各种实施方式涉及方法,用于在哺乳动物中产生能够制造和分泌
胰岛素的肠内分泌细胞,包括向该哺乳动物施用该化合物或其药用可接受的盐或互变异构体的有效量。